CAMBRIDGE, Mass -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in ...

Students of Senior Course 47 at the Armed Forces Command and Staff College (AFCSC), Jaji, have concluded a week-long study tour of Imo State, focused on exploring grassroots intelligence strategies to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination ...